Stem Cell Therapies for Progressive Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration. MS patients typically present with relapsing-remitting (RR) course, manifesting as sporadic attacks neurological symptoms including ataxia, fatigue, sensory impairment. While there are several effective disease-modifying therapies able to address relapses associated RRMS, most will inevitably advance progressive course marked gradual irreversible accrual disabilities. Therapeutic intervention in (PMS) suffers from lack well-characterized biological targets and, hence, dearth successful drugs. The few medications approved for treatment PMS limited their efficacy active forms disease, have little impact on slowing degeneration, fail promote repair. In looking these unmet needs, multifactorial therapeutic benefits stem cell particularly compelling. Ostensibly providing neurotrophic support, immunomodulation replacement, transplantation holds substantial promise combatting complex pathology neuroinflammation. Herein, we explore current state preclinical clinical evidence supporting use cells treating discuss prospective hurdles impeding translation into revolutionary regenerative medicines.